Researchers discovered that the enzyme TYK2 alters the tau protein, promoting its accumulation in the brain, a process linked ...

The JAK3/TYK2 inhibitor ritlecitinib received FDA approval for this indication in 2023; brepocitinib, a TYK2/JAK1 inhibitor, ...

Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, ...

TYK2 enzyme changes tau protein from a protective role to a harmful one, contributing to Alzheimer’s disease progression.

Researchers at Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital and collaborating institutions discovered that the enzyme ...

Researchers at Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas ...

Scientists have discovered that the enzyme TYK2 modifies tau proteins, leading to their accumulation in the brain—a key ...

Q3 2024 Earnings Call Transcript November 3, 2024 Operator: Good day, and welcome to the Kymera Therapeutics Third Quarter ...

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical ...

Biogen Inc. has identified non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, autoimmune disease, cardiovascular disorders, fibrosis, inflammatory ...